Spread | 0.17 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 4.12 |
Open | 4.36 |
1-Year Change | 497.26% |
Day's Range | 4.08 - 4.36 |
SAB Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.
BRIEF: For the nine months ended 30 September 2021, SAB Biotherapeutics Inc revenues was not reported. Net income totaled to $440K.